Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Non-Current Debt for 5 consecutive years, with $448.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 14.95% to $448.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $448.5 million through Dec 2025, up 14.95% year-over-year, with the annual reading at $448.5 million for FY2025, 14.95% up from the prior year.
  • Non-Current Debt hit $448.5 million in Q4 2025 for Ascendis Pharma A, up from $390.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $448.5 million in Q4 2025 to a low of $112.1 million in Q4 2021.
  • Historically, Non-Current Debt has averaged $317.2 million across 5 years, with a median of $390.1 million in 2024.
  • Biggest five-year swings in Non-Current Debt: surged 252.82% in 2022 and later tumbled 39.32% in 2023.
  • Year by year, Non-Current Debt stood at $112.1 million in 2021, then soared by 252.82% to $395.4 million in 2022, then crashed by 39.32% to $239.9 million in 2023, then surged by 62.6% to $390.1 million in 2024, then grew by 14.95% to $448.5 million in 2025.
  • Business Quant data shows Non-Current Debt for ASND at $448.5 million in Q4 2025, $390.1 million in Q4 2024, and $239.9 million in Q4 2023.